Global Etomidate Injections Market Trends, Business Overview, Industry Growth and Forecast to 2022-2028

The global etomidate injections market is anticipated to grow at a considerable CAGR 6% during the forecast period (2022-2028). Etomidate injections are hypnotic drugs used as anesthesia in several medical procedures, including tracheal intubation, cardioversion, and electroconvulsive therapy. The major factor attributing to the growth of the global etomidate injections market includes the rising application of etomidate injection in cardioversion procedures due to increasing cases of atrial fibrillation. According to the report published by the National Center for Biotechnology Information (NCBI) in February 2021, atrial fibrillation is an irregular heart rate causing poor blood flow in the body. The organization estimates that around 6 million to 12 million people will be suffering from atrial fibrillation in the US alone by 2050. The report also describes that an estimation of around 17.9 million people will suffer from atrial fibrillation in Europe by 2060.

In addition, the application of etomidate injections is also increasing in electroconvulsive therapy due to the rising prevalence of epilepsy across the globe. According to the report published by the World Health Organization (WHO) in February 2022, one of the most common neurological diseases is epilepsy with around 50 million people having epilepsy across the globe. Furthermore, the increasing application of etomidate injections for tracheal intubation during intensive and critical care is also driving the growth of the market. According to the Society of Critical Care Medicine (SCCM), around 5 million people are admitted to intensive care units (ICUs) every year in the US. These intensive care units (ICUs) provide intensive or invasive care and monitoring to the patients along with support to their airways for better breathing and circulation. Thus, boosting the demand for etomidate injections.

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in December 2020, Caplin Sterile, a subsidiary of Caplin Point Laboratories got Abbreviated New Drug Application (ANDA) approval from the USFDA for Etomidate Injection USP. This is the generic version of AMIDATE (Etomidat) Injection of Hospira Inc.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
  • By End-user
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Pfizer Inc., American Regents Inc., Hikma Pharmaceuticals PLC, Zydus Healthcare Inc., and Viatris Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Etomidate Injections  Market Report by Segment

By Application

• Dislocated Joints
• Tracheal Intubation
• Cardioversion
• Electroconvulsive therapry

By End-user

• Hospitals
• Ambulatory Surgical centers
• Other